Market Research Logo

US Market Report for Syringes and Needles - MedCore

The total U.S. market for syringes and needles comprises the syringe segment and the needle segment.The syringe segment comprises the conventional syringe, sliding sleeve safety syringe, retractable safetysyringe, hinged safety syringe and insulin syringe sub-segments. The insulin syringe sub-segment includesinsulin syringes sold in the personal and professional markets. The needle segment comprises theconventional needle, shielding safety needle, pivoting safety needle and insulin pen needle subsegments.In 2015, the needle segment represented just over 50% of the total syringe and needle market. Thevalue of the total syringe and needle market is expected to increase over the forecast period. Growth willbe driven by increases in the insulin pen needle and pivoting safety needle sub-segments. Growth will belimited by declines in the insulin syringe and conventional needle sub-segments.


EXECUTIVE SUMMARY
1.1 U.S. VASCULAR ACCESS DEVICES AND ACCESSORIES MARKET OVERVIEW
1.2 COMPETITIVE LANDSCAPE
1.3 MARKET TRENDS
1.4 KEY MARKET DEVELOPMENTS
1.5 MARKETS INCLUDED
1.6 PROCEDURES INCLUDED
1.7 PROCEDURE CODES INVESTIGATED
1.8 KEY REPORT UPDATES
1.9 VERSION HISTORY
RESEARCH METHODOLOGY
2.1 RESEARCH SCOPE
2.2 IDATA’S 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
3.1 BASIC ANATOMY
3.1.1 Human Vascular System
3.2 VASCULAR PATHOLOGY AND DISORDERS
3.2.1 Cancer
3.2.2 End-Stage Renal Disease
3.2.3 Diabetes
3.3 PATIENT DEMOGRAPHICS
3.3.1 Cancer
3.3.1.1 Digestive Cancer
3.3.1.2 Genital Cancer
3.3.1.3 Breast Cancer
3.3.1.4 Respiratory Cancer
3.3.1.5 Urinary Cancer
3.3.1.6 Skin Cancer
3.3.1.7 Lymphoma
3.3.1.8 Endocrine System Cancer
3.3.1.9 Leukemia
3.3.1.10 Oral Cavity/Larynx
3.3.1.11 Myeloma
3.3.1.12 Brain/Other Nervous System
3.3.1.13 Soft Tissue (including heart)
3.3.1.14 Bones and Joints
3.3.1.15 Eye and Orbit
3.3.2 End-Stage Renal Disease
3.3.2.1 End-Stage Renal Disease Incidence
3.3.2.1.1 End-Stage Renal Disease Incident Cases by Modality
3.3.2.1.2 End-Stage Renal Disease Incident Cases by Age Group
3.3.2.1.3 End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy
3.3.2.2 Vascular Access Use at Hemodialysis Initiation
3.3.2.2.1 Vascular Access Use During First Year of Hemodialysis
3.3.2.2.1.1 Vascular Access Use During First Year of Hemodialysis by Age Group
3.3.2.3end- Stage Renal Disease Prevalence
3.3.2.3.1 End-Stage Renal Disease Prevalent Cases by Modality
3.3.2.3.1.1 Prevalent Hemodialysis Patients by Vascular Access Type
3.3.2.3.2 End-Stage Renal Disease Prevalent Cases by Age Group
3.3.2.3.3 End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy
3.3.3 Diabetes
3.3.3.1 Diagnosed Diabetes Incidence Amongst Adults
3.3.3.1.1 Diagnosed Diabetes Incidence Amongst Adults by State
3.3.3.2 Diagnosed Diabetes Prevalence Amongst Adults
3.3.3.2.1 Diagnosed Diabetes Prevalence Amongst Adults by Medication Status
3.3.3.2.2 Diagnosed Diabetes Prevalence Amongst Adults by State and Age Group
3.3.3.2.3 Diagnosed Diabetes Prevalence Amongst Adults by State and Gender
PRODUCT ASSESSMENT
4.1 PRODUCT PORTFOLIOS
4.1.1 Syringe and Needles
4.1.1.1 Introduction
4.1.1.2 Allison Medical
4.1.1.2.1 SureComfort™
4.1.1.3 B. Braun
4.1.1.3.1 Injekt®
4.1.1.3.2 Other Syringe & Needle Offerings
4.1.1.4 Becton Dickinson
4.1.1.4.1 BD™ Insulin Syringes
4.1.1.4.2 BD™ Allergy Syringes
4.1.1.4.3 BD™ Tuberculin Syringes
4.1.1.4.4 BD™ Syringes & Needles
4.1.1.4.5 BD PrecisionGlide™ Needles
4.1.1.4.6 BD Safety-Lok™ Syringes
4.1.1.4.7 BD SafetyGlide™ Syringes & Needles
4.1.1.4.8 BD Eclipse™ Needles and Syringes
4.1.1.4.9 BD Integra™ Needles and Syringes
4.1.1.4.10 BD AutoShield™
4.1.1.5 Cardinal Health
4.1.1.5.1 Cardinal Health™
4.1.1.6 Delta Hi-Tech, Inc.
4.1.1.6.1 AIMSCO®
4.1.1.7 Medical Plastic Devices, Inc.
4.1.1.7.1 Insupen®
4.1.1.8 Medtronic
4.1.1.8.1 Magellan™
4.1.1.8.2 Monoject™
4.1.1.9 MYCO Medical
4.1.1.9.1 Dispovan®
4.1.1.10 Nipro Medical
4.1.1.10.1 Nipro™
4.1.1.11 Novo Nordisk
4.1.1.11.1 NovoFine®
4.1.1.11.2 NovoTwist®
4.1.1.12 Owen Mumford, Inc.
4.1.1.12.1 Unifine®
4.1.1.13 Perrigo
4.1.1.13.1 Clickfine®
4.1.1.14 Protectus Medical Devices
4.1.1.14.1 Protectus®
4.1.1.15 ReliOn
4.1.1.15.1 ReliOn®
4.1.1.16 Retractable Technologies, Inc.
4.1.1.16.1 VanishPoint®
4.1.1.16.2 Patient Safe®
4.1.1.17 Revolutions Medical
4.1.1.17.1 ReVac™
Safety 1 st 4.1.1.18 Medical
4.1.1.18.1 Safe-1®
4.1.1.19 Smiths Medical
4.1.1.19.1 Needle-Pro®
4.1.1.20.1 SOL-CARE®
4.1.1.20.2 SOL-M™
4.1.1.20.3 SOL-GUARD™
4.1.1.21 STAT Medical Devices
4.1.1.21.1 Super-Fine™
4.1.1.22 Terumo
4.1.1.22.1 SurGuard®
4.1.1.22.2 TERUMO®
4.1.1.23 UltiCare
4.1.1.23.1 UltiCare®
SYRINGE & NEEDLE MARKET
5.1 MARKET OVERVIEW
5.2 MARKET ANALYSIS AND FORECAST
5.2.1 Total Syringe Market
5.2.1.1 Conventional Syringe Market
5.2.1.2 Sliding Sleeve Safety Syringe Market
5.2.1.3 Retractable Safety Syringe Market
5.2.1.4 Hinged Safety Syringe Market
5.2.1.5 Insulin Syringe Market
5.2.1.5.1.1 Personal Insulin Syringe Market
5.2.1.5.1.2 Professional Insulin Syringe Market
5.2.2 Total Needle Market
5.2.2.1 Conventional Needle Market
5.2.2.2 Shielding Safety Needle Market
5.2.2.3 Pivoting Safety Needle Market
5.2.2.4 Insulin Pen Needle Market
5.3 DRIVERS AND LIMITERS
5.3.1 Market Drivers
5.3.2 Market Limiters
5.4 COMPETITIVE MARKET SHARE ANALYSIS
List of Chart
Chart 0-1: Vascular Access Device Market by Segment, U.S., 2012 – 2022
Chart 0-2: Vascular Access Device Market Overview, U.S., 2015 and 2022
Chart 3-1: Male Incidence, Digestive Cancer, U.S., 2016
Chart 3-2: Male Deaths, Digestive Cancer, U.S., 2016
Chart 3-3: Female Incidence, Digestive Cancer, U.S., 2016
Chart 3-4: Female Deaths, Digestive Cancer, U.S., 2016
Chart 3-5: Male Incidence, Genital Cancer, U.S., 2016
Chart 3-6: Male Deaths, Genital Cancer, U.S., 2016
Chart 3-7: Female Incidence, Genital Cancer, U.S., 2016
Chart 3-8: Female Deaths, Genital Cancer, U.S., 2016
Chart 3-9: Incidence by Gender, Breast Cancer, U.S., 2016
Chart 3-10: Deaths by Gender, Breast Cancer, U.S., 2016
Chart 3-11: Male Incidence, Respiratory Cancer, U.S., 2016
Chart 3-12: Male Deaths, Respiratory Cancer, U.S., 2016
Chart 3-13: Female Incidence, Respiratory Cancer, U.S., 2016
Chart 3-14: Female Deaths, Respiratory Cancer, U.S., 2016
Chart 3-15: Male Incidence, Urinary Cancer, U.S., 2016
Chart 3-16: Male Deaths, Urinary Cancer, U.S., 2016
Chart 3-17: Female Incidence, Urinary Cancer, U.S., 2016
Chart 3-18: Female Deaths, Urinary Cancer, U.S., 2016
Chart 3-19: Male Incidence, Skin Cancer, U.S., 2016
Chart 3-20: Male Deaths, Skin Cancer, U.S., 2016
Chart 3-21: Female Incidence, Skin Cancer, U.S., 2016
Chart 3-22: Female Deaths, Skin Cancer, U.S., 2016
Chart 3-23: Male Incidence, Lymphoma Cancer, U.S., 2016
Chart 3-24: Male Deaths, Lymphoma Cancer, U.S., 2016
Chart 3-25: Female Incidence, Lymphoma Cancer, U.S., 2016
Chart 3-26: Female Deaths, Lymphoma Cancer, U.S., 2016
Chart 3-27: Male Incidence, Endocrine Cancer, U.S., 2016
Chart 3-29: Female Incidence, Endocrine Cancer, U.S., 2016
Chart 3-30: Female Deaths, Endocrine Cancer, U.S., 2016
Chart 3-31: Male Incidence, Leukemia Cancer, U.S., 2016
Chart 3-32: Male Deaths, Leukemia Cancer, U.S., 2016
Chart 3-33: Female Incidence, Leukemia Cancer, U.S., 2016
Chart 3-34: Female Deaths, Leukemia Cancer, U.S., 2016
Chart 3-35: Male Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
Chart 3-36: Male Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
Chart 3-37: Female Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
Chart 3-38: Female Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
Chart 3-39: Incidence by Gender, Myeloma Cancer, U.S., 2016
Chart 3-40: Deaths by Gender, Myeloma Cancer, U.S., 2016
Chart 3-41: Incidence by Gender, Brain/Other Nervous System Cancer, U.S., 2016
Chart 3-42: Deaths by Gender, Brain/Other Nervous System Cancer, U.S., 2016
Chart 3-43: Incidence by Gender, Soft Tissue Cancer, U.S., 2016
Chart 3-44: Deaths by Gender, Soft Tissue Cancer, U.S., 2016
Chart 3-45: Incidence by Gender, Bone and Joint Cancers, U.S., 2016
Chart 3-46: Deaths by Gender, Bone and Joint Cancers, U.S., 2016
Chart 3-47: Incidence by Gender, Eye and Orbit Cancers, U.S., 2016
Chart 3-48: Deaths by Gender, Eye and Orbit Cancers, U.S., 2016
Chart 3-49: End-Stage Renal Disease Incident Cases, U.S., 1996 – 2015
Chart 3-50: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996 – 2015
Chart 3-51: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996 – 2015
Chart 3-52: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996 – 2015 83
Chart 3-53: Vascular Access Use at Hemodialysis Initiation, U.S., 2005 – 2015
Chart 3-54: Vascular Access Use During First Year of Hemodialysis, U.S., 2013 – 2014
Chart 3-55: End-Stage Renal Disease Prevalent Case Count, U.S., 1996 – 2015
Chart 3-56: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996 – 2015
Chart 3-57: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003 – 2015
Chart 3-58: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996 – 2015
Chart 3-59: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996 – 2015
Chart 3-60: Diagnosed Diabetes Incidence Count Adults, U.S., 1997 – 2015
Chart 5-1: Syringe & Needle Market by Device Type, U.S., 2012 – 2022
Chart 5-2: Syringe & Needle Market Breakdown, U.S., 2015
Chart 5-3: Syringe & Needle Market Breakdown, U.S., 2022
Chart 5-4: Total Syringe Market, U.S., 2012 – 2022
Chart 5-5: Conventional Syringe Market, U.S., 2012 – 2022
Chart 5-6: Sliding Sleeve Safety Syringe Market, U.S., 2012 – 2022
Chart 5-7: Retractable Safety Syringe Market, U.S., 2012 – 2022
Chart 5-8: Hinged Safety Syringe Market, U.S., 2012 – 2022
Chart 5-9: Insulin Syringe Market, U.S., 2012 – 2022
Chart 5-10: Personal Insulin Syringe Market, U.S., 2012 – 2022
Chart 5-11: Professional Insulin Syringe Market, U.S., 2012 – 2022
Chart 5-12: Total Needle Market, U.S., 2012 – 2022
Chart 5-13: Conventional Needle Market, U.S., 2012 – 2022
Chart 5-14: Shielding Safety Needle Market, U.S., 2012 – 2022
Chart 5-15: Pivoting Safety Needle Market, U.S., 2012 – 2022
Chart 5-16: Insulin Pen Needle Market, U.S., 2012 – 2022
Chart 5-17: Leading Competitors, Syringe & Needle Market, U.S., 2015
Chart 5-18: Leading Competitors, Insulin Syringe & Pen Needle Market, U.S., 2015
List of Figures
Figure 0-1: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (1 of 2)
Figure 0-2: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (2 of 2)
Figure 0-3: Companies Researched in Report, U.S., 2015
Figure 0-4: Factors Impacting the Vascular Access Device and Accessories Market by Segment, U.S.
Figure 0-5: Recent Events in the Vascular Access Device and Accessories Market, U.S., 2012 – 2015
Figure 0-6: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (1 of 3)
Figure 0-7: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (2 of 3)
Figure 0-8: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (3 of 3)
Figure 0-9: Vascular Access Devices & Accessories Procedures Covered, U.S., 2015
Figure 0-10: Procedural Codes, U.S., 2015
Figure 0-11: Key Report Updates, U.S., 2014 and 2016 (1 of 2)
Figure 0-12: Key Report Updates, U.S., 2014 and 2016 (2 of 2)
Figure 0-13: Version History
Figure 3-1: Digestive Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-2: Genital Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-3: Breast Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-4: Respiratory Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-5: Urinary Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-6: Skin Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-7: Lymphoma Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-8: Endocrine Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-9: Leukemia Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-10: Oral Cavity/Larynx Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-11: Myeloma Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-12: Brain/Other Nervous System Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-13: Soft Tissue (Including Heart) Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-14: Bone and Joint Cancer Statistics by Type and Gender, U.S., 2016
Figure 3-15: Eye and Orbit Statistics by Type and Gender, U.S., 2016
Figure 3-16: End-Stage Renal Disease Incident Cases, U.S., 1996 – 2015
Figure 3-17: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996 – 2015
Figure 3-18: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996 – 2015
Figure 3-19: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996 – 2015
Figure 3-20: Vascular Access Use at Hemodialysis Initiation, U.S., 2005 – 2015
Figure 3-21: Vascular Access Use During First Year of Hemodialysis, U.S., 2013 – 2014
Figure 3-22: Vascular Access Use During First Year of Hemodialysis by Age Group, U.S., 2013 – 2014
Figure 3-23: Vascular Access Use During First Year of Hemodialysis by Sex, U.S., 2013 – 2014
Figure 3-24: End-Stage Renal Disease Prevalent Case Count, U.S., 1996 – 2015
Figure 3-25: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996 – 2015
Figure 3-26: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003 – 2015
Figure 3-27: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996 – 2015
Figure 3-28: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996 – 2015
Figure 3-29: Diagnosed Diabetes Incidence Count Adults, U.S., 1997 – 2015
Figure 3-30: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (1 of 2)
Figure 3-31: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (2 of 2)
Figure 3-32: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997 – 2015
Figure 3-33: Diagnosed Diabetes Prevalence Count Adults by Medication Status, U.S., 1997 – 2015
Figure 3-34: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (1 of 2)
Figure 3-35: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (2 of 2)
Figure 3-36: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (1 of 2)
Figure 3-37: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (2 of 2)
Figure 5-1: Syringe & Needle Market by Device Type, U.S., 2012 – 2022 (US$M)
Figure 5-2: Total Syringe Market, U.S., 2012 – 2022
Figure 5-3: Conventional Syringe Market, U.S., 2012 – 2022
Figure 5-4: Sliding Sleeve Safety Syringe Market, U.S., 2012 – 2022
Figure 5-5: Retractable Safety Syringe Market, U.S., 2012 – 2022
Figure 5-6: Hinged Safety Syringe Market, U.S., 2012 – 2022
Figure 5-7: Insulin Syringe Market, U.S., 2012 – 2022
Figure 5-8: Personal Insulin Syringe Market, U.S., 2012 – 2022
Figure 5-9: Professional Insulin Syringe Market, U.S., 2012 – 2022
Figure 5-10: Total Needle Market, U.S., 2012 – 2022
Figure 5-11: Conventional Needle Market, U.S., 2012 – 2022
Figure 5-12: Shielding Safety Needle Market, U.S., 2012 – 2022
Figure 5-13: Pivoting Safety Needle Market, U.S., 2012 – 2022
Figure 5-14: Insulin Pen Needle Market, U.S., 2012 – 2022
Figure 5-15: Drivers and Limiters, Syringe & Needle Market, U.S., 2015
Figure 5-16: Leading Competitors, Syringe & Needle Market, U.S., 2015
Figure 5-17: Leading Competitors, Insulin Syringe & Pen Needle Market, U.S., 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report